DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

IQV·IQVIA Holdings Inc.

$.
-. (-.%)
High
$167.09
Open
$166.18
Market Cap
28.02B
52W High
$247.05
Low
$163.24
P. Close
$167.90
P/E
20.23
52W Low
$134.65
Fwd P/E
55.35
Mean Target
-
Technical Score (1D)
36
SELL
News Sentiment
57
BULLISH
Artisan Partners' Value Fund has initiated a new position in IQVIA Holdings (IQV) during the first quarter of 2026. This strategic addition was made despite a market environment that has recently favored momentum stocks over quality factors, impacting the fund's overall performance. The fund manager's decision suggests a belief in IQV's long-term value creation potential, even amidst current market volatility and sector-specific headwinds. Investors will be watching to see if this conviction translates into sustained performance for IQV.
Earnings Summary
IQVIA Holdings, Inc. operates within the Healthcare sector, specifically in the Diagnostics & Research industry, providing technology, analytics, and services to life sciences and healthcare clients. The company offers comprehensive solutions across the drug development and commercialization lifecycle, utilizing three primary segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. IQVIA supports pharmaceutical, biotechnology, and medical device companies by aiding in clinical trials, offering data-driven insights, and developing commercialization strategies. In recent quarterly performance, IQVIA has consistently met or exceeded analyst expectations for both EPS and revenue. For Q1 2026, the company reported EPS of $2.90 against an estimate of $3.04243, and revenue of $4.151 billion against an estimate of $4.246 billion. This represents a miss on both EPS and revenue estimates for this quarter. However, looking at the prior quarters, Q4 2024 saw EPS of $3.12 vs $3.10883 and revenue of $3.958 billion (no estimate provided). Q1 2025 had EPS of $2.70 vs $2.63225 and revenue of $3.829 billion (no estimate provided). Q2 2025 had EPS of $2.81 vs $2.77039 and revenue of $4.017 billion (no estimate provided). Q3 2025 had EPS of $3.00 vs $2.97588 and revenue of $4.100 billion (no estimate provided). Historically, IQVIA has shown a strong track record of meeting or beating analyst estimates, particularly in EPS, with a notable miss in Q1 2026. Recent news highlights a strong first quarter with record revenue and EPS, driven by robust client demand and accelerated organic growth in Commercial Solutions, attributed to AI and advanced analytics. The company also expanded a strategic collaboration with Kexing Biopharm to accelerate global biosimilar development using AI. Furthermore, a significant increase in its share repurchase authorization signals management's confidence. Investors will be watching for continued strength in Commercial Solutions, the impact of AI-driven growth, and whether the company can regain its consistent pattern of exceeding estimates after the Q1 2026 miss.

EPS

EstBeatMiss
$2.56$2.72$2.88$3.03$3.19Q4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.03 - -
Q1'26$3.04$2.90-4.7%
Q3'25$2.98$3.00+0.8%
Q2'25$2.77$2.81+1.4%
Q1'25$2.63$2.70+2.6%
Q4'24$3.11$3.12+0.4%

Revenue

EstBeatMiss
$3.8B$3.9B$4.1B$4.3B$4.4BQ4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.4B - -
Q1'26$4.2B$4.2B-2.3%
Q3'25 - $4.1B -
Q2'25 - $4.0B -
Q1'25 - $3.8B -
Q4'24 - $4.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

IQV Stock Snapshot

IQV is currently trading at $165.55, giving IQVIA Holdings Inc. a market cap of 28.02B and a P/E ratio of 20.2. Today's range spans $163.24–$167.09, with shares opening at $166.18 and moving down $2.35 (1.4%) from the prior close. DailyIQ's technical score sits at 36/100 (HOLD) with a news sentiment reading of 57/100.

Over the past year IQV has traded between $134.65 and $247.05 - the current price is +22.9% off the 52-week low and -33.0% from the high.

IQV is in a holding pattern - 36/100 technical score, HOLD signal, price at $165.55 (in the lower half of its 52-week range), sentiment neutral at 57/100. (P/E: 20.2) At 28.02B in Healthcare market cap, HOLD phases like this are where the thesis is re-evaluated and position sizing decisions get made by both longs and shorts. Annual range: $134.65–$247.05. The next catalyst, not the current setup, determines the exit from this range.

In neutral phases, large-cap Healthcare names like IQV are often where sector rotation debates play out quietly — at 28.02B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 36/100 (HOLD) and neutral sentiment (57/100) at $165.55 (in the lower half of its 52-week range) describe a stock that is being considered rather than avoided.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…